JP6343755B2 - G−csfを用いた樹状細胞の調製方法 - Google Patents
G−csfを用いた樹状細胞の調製方法 Download PDFInfo
- Publication number
- JP6343755B2 JP6343755B2 JP2015500336A JP2015500336A JP6343755B2 JP 6343755 B2 JP6343755 B2 JP 6343755B2 JP 2015500336 A JP2015500336 A JP 2015500336A JP 2015500336 A JP2015500336 A JP 2015500336A JP 6343755 B2 JP6343755 B2 JP 6343755B2
- Authority
- JP
- Japan
- Prior art keywords
- csf
- monocytes
- dendritic cell
- interleukin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims description 205
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims description 73
- 238000000034 method Methods 0.000 title claims description 56
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims 4
- 210000001616 monocyte Anatomy 0.000 claims description 121
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 55
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 55
- 102000004127 Cytokines Human genes 0.000 claims description 52
- 108090000695 Cytokines Proteins 0.000 claims description 52
- 230000001939 inductive effect Effects 0.000 claims description 41
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 33
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 102000004388 Interleukin-4 Human genes 0.000 claims description 28
- 108090000978 Interleukin-4 Proteins 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 102000013462 Interleukin-12 Human genes 0.000 claims description 15
- 108010065805 Interleukin-12 Proteins 0.000 claims description 15
- 102000003816 Interleukin-13 Human genes 0.000 claims description 15
- 108090000176 Interleukin-13 Proteins 0.000 claims description 15
- 102000003812 Interleukin-15 Human genes 0.000 claims description 15
- 108090000172 Interleukin-15 Proteins 0.000 claims description 15
- 102000000588 Interleukin-2 Human genes 0.000 claims description 15
- 108010002350 Interleukin-2 Proteins 0.000 claims description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims description 15
- 108090001005 Interleukin-6 Proteins 0.000 claims description 15
- 229940100601 interleukin-6 Drugs 0.000 claims description 15
- 102000000646 Interleukin-3 Human genes 0.000 claims description 14
- 108010002386 Interleukin-3 Proteins 0.000 claims description 14
- 229940076264 interleukin-3 Drugs 0.000 claims description 14
- 108010002586 Interleukin-7 Proteins 0.000 claims description 13
- 229940100994 interleukin-7 Drugs 0.000 claims description 13
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 12
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 12
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 11
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 238000002659 cell therapy Methods 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 108010029697 CD40 Ligand Proteins 0.000 claims description 7
- 102100032937 CD40 ligand Human genes 0.000 claims description 7
- 102100020880 Kit ligand Human genes 0.000 claims description 7
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 7
- 108700014844 flt3 ligand Proteins 0.000 claims description 6
- 229940117681 interleukin-12 Drugs 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 73
- 238000002617 apheresis Methods 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 28
- 229940028885 interleukin-4 Drugs 0.000 description 26
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 23
- 230000006698 induction Effects 0.000 description 23
- 230000004069 differentiation Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 229940029030 dendritic cell vaccine Drugs 0.000 description 15
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 14
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 14
- 102100021592 Interleukin-7 Human genes 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 9
- 108010075704 HLA-A Antigens Proteins 0.000 description 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102100022297 Integrin alpha-X Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 101150013553 CD40 gene Proteins 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102100035793 CD83 antigen Human genes 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108010029961 Filgrastim Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010011491 CD11c Antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000911996 Homo sapiens CD5 antigen-like Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000051875 human CD5L Human genes 0.000 description 1
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
患者:
90例の進行癌患者の108例(乳癌(17)、結腸/直腸癌(19)、肺癌(12)、卵巣癌(11)、膵臓癌(33)、胃癌(16)を含む)のアフェレーシス(成分採血)実施患者を対象として、GM-CSF(Granulocyte Macrophage colony-stimulating Factor:顆粒白血球-マクロファージ・コロニー刺激因子)及びinterleukin(IL)-4を用いた単球由来の樹状細胞(DC)作製結果について分析した。108例中、47例は、成分採血の24時間前以内に患者にrhG-CSF(遺伝子組換えヒトG-CSF(顆粒球コロニー刺激因子)製剤を投与し、26例は24〜96時間前に投与した。また、35例はG-CSF非投与群とした。ヒトG-CSF製剤としては、グラン(商品名)又はノイトロジン(商品名)を用い、それぞれ75μg、100μgを皮下注射により投与した。
5200mlの患者末梢血から、成分採血装置(AS TEC204, Fresenius, Germany)を使って、処理量400ml×13サイクルによって、185mlの末梢血単核細胞を回収した。500 ng/mlのGM-CSF(Primmune Inc., Kobe, Japan)及び250 ng/mlのIL-4 (R&D Systems Inc., Minneapolis, MN)添加AIM-V培地(Gibco, Gaithersburg, MD)を用いた接着法による5日間培養で未熟なDCs(immatureDCs; iDCs)を得た。iDCsをOK-432(10μg/ml)とprostaglandin E2(50 ng/ml; Daiichi Fine Chemical Co. LTD., Toyama, Japan)を添加した培地を用いて、24時間培養することにより成熟したDCs(matureDCs: mDCs)を調製した。mDCsはDC療法のための投与日まで液体窒素保管され、治療時に解凍、洗浄後、生理食塩水に再浮遊した。
CD14-, HLA-DR+, HLA-, ABC+, CD80+, CD83+, CD86+, CD40+, CCR7+の表現型は、mDCsとして定義される。凍結保管サンプル中のDCの生細胞に対して、以下の抗体パネルを適用しFACSCalibur(BD Biosciences, San Jose, CA)で測定した: FITC標識抗ヒトCD14(クローン61D3,eBiocience,San Diego,CA)、CD40(クローン5C3,eBiocience)、CD80(クローンL307.4,BD Biosciences)、HLA-ABC(クローンW6/32,eBiocience)、CD3(クローンSK7,BD Biosciences)、PE標識抗ヒトCD11c(クローンB-ly6,BD Biosciences)、CD83(クローンHB15e,eBiocience)、CD86(クローンIT2.2,eBiocience)、CD19(クローン4G7,BD Biosciences)、HLA-DR(クローンLN3,eBiocience)。
hrG-CSF(75μg filgrastim、グラン(登録商標))によって増幅される接着因子遺伝子群をスクリーニングし同定した。DC療法を行う患者4名を対象とし、hrG-CSFの投与前及び投与後の末梢血を採取した。比重分離法により単球を分離後、CD14 Micro Bead(Miltenyi Biotec)を反応させ、Auto MACS(磁気分離装置)を用いてCD14陽性細胞を分離純化した。純度98%のCD14陽性細胞よりQIAamp RNA Blood Mini Kit (QIAGEN)を用いてRNAを抽出し、RT2 First Strand Kit(QIAGEN)を用いてcDNAを合成した。RT2 SYBR(登録商標) Green/ROXTMqPCR Master Mix(QIAGEN)を用いてPCR反応液を作製し、RT2 ProfilerTM PCR Array(QIAGEN)のウェルに添加した。ABI 7900 real time PCR(Applied Biosystems, Maryland)により95℃:10min(95℃:15sec→60℃:1min)40サイクルの条件でPCRを行い、その後95℃:15sec、 60℃:15sec、 95℃:15secの条件下で解離曲線を得た。
DC調製工程におけるMMP-9の影響を評価するために、単球MMP-9阻害薬の存在下及び未処理を対象(N=6)としてmDCsの製造サンプルの比較検討を行った。成分採血の16〜18時間前に、75μgのrhG-CSFを投与されている患者由来の末梢血単球をフィコール勾配遠心分離を使って分離した。末梢血単核球は6mLのAIM-V媒体で100mmディッシュにつき8×107細胞で種をまかれて、細胞接着のために、5%CO2で37℃で静置した。非接着細胞の除去の後、iDCsを製造するためにIL-4(50ng/mL)とGM-CSF(50ng/mL)添加AIM-V培地で、5日間接着法により培養された。成熟工程のために、さらに24時間OK432(10ug/mL)、IL-4(5ng/mL)、GM-CSF(5ng/mL)とプロスタグランジンE-2(50ng/ml)を含んでいるAIM-V培地で、iDCsは培養され,浮遊細胞を回収した。MMP-9阻害薬I (IC50=5nM) (Calbiochem Corp., San Diego, CA, USA)は、各々の工程において培地に加えられ,mDCs製造産物の生細胞と接種した単球数との比を計算し比較した。
IBM SPSS Statistics 21.0, (International Business Machines Corp., New York)を用いて解析した。
108例の患者のアフェレーシスを行う日に計数した末梢血単球数とhrG-CSF投与後のアフェレーシス単球数の相関性を図2に示す(R=0.828, p<0.0001, N=108であった。(Spearman’s rank-order correlation))。図に示すようにアフェレーシス単球数と末梢血単球数は相関していた。
G-CSFをアフェレーシスの前投与無、およびアフェレーシス24時間以前投与群(I))、あるいはアフェレーシスの18〜22時間前に投与した(24時間以内に投与した群(II))。実施例1と同様の方法で、GM-CSFとIL-4でアフェレーシス由来の末梢血単核球を培養して、成熟型DCワクチンを作製した。改変型WT1(HLA-A*24:02)ペプチドに適合する樹状細胞ワクチン療法を群IおよびIIを対象とした。1×E7(10の7乗)DCワクチンを2週毎に1コース7回完遂例に対して、WT1-CTLを検出するためにDCワクチン初回および7回目の改変型WT1(HLA-A*24:02)ペプチドテトラマー解析により比較分析した。培養操作を加えず、採血分離した末梢血単核球を用いて治療前後においてWT1-CTLが増加、かつCD8+細胞に対して0.08%以上を陽性と判定した。
Claims (10)
- 50〜100μgのG-CSFを投与した被験体からG-CSF投与後24時間以内に回収したMMP-9(matrix metalloproteinase-9)の発現が亢進している単球を、樹状細胞誘導活性を有する少なくとも1種類のサイトカインを含む培地で培養することを含む、単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 回収した単球におけるMMP-9(matrix metalloproteinase-9)の発現が、G-CSF投与前の単球に対して5倍以上亢進している、請求項1記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 樹状細胞の細胞傷害性T細胞(CTL)の誘導活性が向上している、請求項1又は2に記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 樹状細胞誘導活性を有する少なくとも1種類のサイトカインが、GM-CSF、IL-4、IL-2(インターロイキン2)、IL-3(インターロイキン3)、IL-6(インターロイキン6)、IL-7(インターロイキン7)、IL-12(インターロイキン12)、IL-13(インターロイキン13)、IL-15(インターロイキン15)、TNF(腫瘍壊死因子)-α、HGF(Hepatocyte growth factor)、TGF(トランスフォーミング増殖因子)-β、CD40リガンド、c-kitリガンド、IFNα(インターフェロンα)、及びflt3リガンドからなる群から選択される少なくとも1種類のサイトカインである、請求項1〜3のいずれか1項に記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 樹状細胞誘導活性を有する少なくとも1種類のサイトカインが、GM-CSFとIL-4又はGM-CSFとIFNαである、請求項1〜4のいずれか1項に記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- さらに、癌特異的抗原を含む培地で培養することを含む、請求項1〜5のいずれか1項に記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 癌特異的抗原がWT1ペプチドである、請求項6記載の単球から樹状細胞療法に用い得る樹状細胞を調製する方法。
- 請求項1〜7のいずれか1項に記載の調製方法により調製された樹状細胞療法に用い得る樹状細胞。
- 請求項1〜7のいずれか1項に記載の調製方法により調製された樹状細胞療法に用い得るヒト樹状細胞を含む医薬組成物。
- 抗癌免疫活性を有し、癌治療に用い得る、請求項9記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013028118 | 2013-02-15 | ||
JP2013028118 | 2013-02-15 | ||
PCT/JP2014/053676 WO2014126250A1 (ja) | 2013-02-15 | 2014-02-17 | G-csfを用いた樹状細胞の調製方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2014126250A1 JPWO2014126250A1 (ja) | 2017-02-02 |
JP6343755B2 true JP6343755B2 (ja) | 2018-06-20 |
Family
ID=51354248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015500336A Active JP6343755B2 (ja) | 2013-02-15 | 2014-02-17 | G−csfを用いた樹状細胞の調製方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6343755B2 (ja) |
WO (1) | WO2014126250A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107532146A (zh) * | 2015-03-17 | 2018-01-02 | 国立大学法人信州大学 | 通过使用ifn的非贴壁培养制备树突状细胞的方法 |
WO2021095700A1 (ja) * | 2019-11-12 | 2021-05-20 | 学校法人金沢医科大学 | 樹状細胞分化誘導培地、及び樹状細胞集団の製造方法 |
JPWO2022097664A1 (ja) * | 2020-11-04 | 2022-05-12 | ||
CN113186160A (zh) * | 2021-04-25 | 2021-07-30 | 大连大学 | 一株猪dc细胞的传代细胞系及其建立方法与应用 |
-
2014
- 2014-02-17 WO PCT/JP2014/053676 patent/WO2014126250A1/ja active Application Filing
- 2014-02-17 JP JP2015500336A patent/JP6343755B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014126250A1 (ja) | 2014-08-21 |
JPWO2014126250A1 (ja) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190167720A1 (en) | Gene editing for immunological destruction of neoplasia | |
JP6182175B2 (ja) | 樹状細胞の製造方法 | |
EP2855668B1 (en) | Methods of obtaining immunosuppressive cells | |
JP6343755B2 (ja) | G−csfを用いた樹状細胞の調製方法 | |
JP5856025B2 (ja) | 単球またはnk細胞を入手する方法 | |
TWI721969B (zh) | 藉由使用干擾素(ifn)之非接著培養之樹突細胞之調製方法 | |
US20050112762A1 (en) | Method for culturing dendritic cells | |
TWI757709B (zh) | 含有nk細胞之細胞集團之製造方法 | |
US20030194395A1 (en) | Th1 cell adoptive immunotherapy | |
EP3516045A1 (en) | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same | |
JP6782503B1 (ja) | 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法 | |
CN113881632A (zh) | 一种提高dc细胞活性的细胞培养基及培养方法 | |
CN110585427B (zh) | 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用 | |
WO2020152661A1 (ja) | Nk細胞を含む細胞集団の製造方法 | |
JP2023153286A (ja) | Nk細胞を含む細胞集団の製造方法 | |
KR101244245B1 (ko) | 결핵균의 Rv0315 단백질을 이용한 수지상 세포의 성숙방법 | |
AU2002365446B2 (en) | Method for culturing dendritic cells | |
Van den Bergh et al. | Enabling interleukin-15 transpresentation in human monocyte-derived dendritic cells by co-electroporation of IL-15 and IL-15Rα mRNA | |
CN116322714A (zh) | 使用血小板裂解物制备树突状细胞的方法 | |
KR20170005243A (ko) | 인간 제대혈 유래 cd34 음성세포를 이용한 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 | |
WO2003046191A1 (en) | Method for culturing dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170213 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20171122 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20171127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180309 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6343755 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |